Back to top
more

Johnson & Johnson (JNJ)

(Delayed Data from NYSE)

$146.14 USD

146.14
6,182,473

-0.68 (-0.46%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $145.99 -0.15 (-0.10%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (202 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Buy Shockwave Medical, Other Pipeline & Regulatory News

J&J (JNJ) is set to buy Shockwave Medical (SWAV). FDA approves AstraZeneca's (AZN) Enhertu for metastatic HER2-positive solid tumors.

J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Unlocking Q1 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why Johnson & Johnson (JNJ) Fell More Than Broader Market

In the latest trading session, Johnson & Johnson (JNJ) closed at $151.59, marking a -0.52% move from the previous day.

Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Abecma

Bristol Myers (BMY) wins FDA approval for CAR T cell immunotherapy, Abecma, in earlier lines of treatment for patients with relapsed or refractory multiple myeloma.

FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma

Following the label expansion, J&J's (JNJ) Carvykti is approved as a second-line treatment for adults with relapsed/refractory myeloma. It was initially approved for use as a fifth- or later-line treatment.

J&J's (JNJ) $13.1B Shockwave Deal to Boost MedTech Cardio

J&J's (JNJ) proposed acquisition of Shockwave Medical (SWAV) is expected to strengthen its Medtech cardiovascular portfolio.

Shaun Pruitt headshot

Acquisition Watch: Time to Buy Johnson & Johnson (JNJ) or ShockWave Medical's (SWAV) Stock?

News of healthcare behemoth Johnson & Johnson (JNJ) acquiring medical device company ShockWave Medical (SWAV) for $13.1 billion made headlines this morning.

Sanghamitra Saha headshot

Time to Tap Healthcare ETFs on Nvidia's AI Ambition?

At Nvidia's last week's GTC AI conference, the company announced partnerships in the healthcare sector, representing a strategic move toward expanding its revenue streams beyond tech sectors.

Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?

Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Johnson & Johnson (JNJ) Stock Moves -0.03%: What You Should Know

The latest trading day saw Johnson & Johnson (JNJ) settling at $157.73, representing a -0.03% change from its previous close.

Sanghamitra Saha headshot

AI ETFs: Q1 of 2024 Update

The year 2023 was crucial in the Artificial Intelligence (AI) industry. So far this year, we have seen Apple's efforts to join the AI race more prudently, Amazon's billion dollar investment in AI start-up and Nvidia's efforts to foray into various industries with AI initiatives.

Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending Stock

Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.

Shockwave Medical (SWAV) Up on Potential Acquisition Rumors

Shockwave Medical's (SWAV) shares gain as rumors about its potential acquisition by an industry giant get media attention.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.

Sanghamitra Saha headshot

4 Best ETF Areas of Q1

Wall Street is poised to conclude the first quarter with robust gains due to a likely dovish Fed and robust economic as well as earnings growth.

Merck (MRK) Gets FDA Approval for New PAH Drug Winrevair

Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.

Why the Market Dipped But Johnson & Johnson (JNJ) Gained Today

In the latest trading session, Johnson & Johnson (JNJ) closed at $155.77, marking a +0.35% move from the previous day.

Fresenius Medical (FMS) to Unveil Training on Augmented Reality

Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.

GE HealthCare (GEHC) Uses AI Solution to Boost Medical Imaging

GE HealthCare's (GEHC) SonoSAMTrack demonstrates its pliability and applicability in ultrasound image segmentation by using NVIDIA's technology.